Pirfenidone

CAS 53179-13-8 27 API suppliersSmall Molecule

Overview

Pirfenidone is a pyridine derivative with antifibrotic properties used to treat idiopathic pulmonary fibrosis by reducing lung fibrosis through modulation of the cytokine cascade. It is believed to exert its therapeutic effects by inhibiting TGF-beta and collagen synthesis and decreasing fibroblast proliferation.

API suppliers (27)

Suppliers of Pirfenidone evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

Where these suppliers are
India19Italy3USA1United Kingdom1

Country recorded for 24 of 27 suppliers.

14 of 27 hold a GMP certificate on record in the EU or UK registers

Showing 25 of 27 suppliers — see the full list in the app.

Patent & exclusivity (US)

Per the FDA Orange Book (38 approved US products), the latest listed US patent on Pirfenidone expires 28 Mar 2037. Generic API sourcing typically opens up once these lapse.

Therapeutic areas

PulmonologyRespiratory Therapy
Verified Supplier Partner

Do you supply Pirfenidone? Get in front of buyers actively sourcing it.

We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.

No cost to enquire · we only reach out with a fit.

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.